INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 421m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN20m ago
Public company

ARQTArcutis Biotherapeutics, Inc.

CIK 0001787306

EDGAR filingsOpen in network
Disclosed transactions56
Buys / sells2 / 31
Max Insider Score46
Connections12with evidence

ARQT · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
MM
Matsuda MasaruEVP, Chief Legal Officer
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M$146K
40.0K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Scott Robert ADirector · Oct 28, 2026
  • ← Insider ofevidence
    Curran TerrieDirector · Aug 28, 2026
  • ← Disclosed trade inevidence
    Gilbert Ray Cisneros, Jr.Purchase disclosed 2026-06-08 · Jun 8, 2026
25
MM
Matsuda MasaruEVP, Chief Legal Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$1.37M
40.0K sh
Nov 4, 2026
Nov 4, 2026
traded Nov 4, 2026
+0d
SEC FORM 4

Evidence

0
MM
Matsuda MasaruEVP, Chief Legal Officer
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M—
40.0K sh
Nov 4, 2026Nov 4, 2026
traded Nov 4, 2026
+0dSEC FORM 4

Evidence

8
MM
Matsuda MasaruEVP, Chief Legal Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$39K
1,219 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

24
BP
Burnett PatrickEVP, Chief Medical Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$30K
943 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

30
WT
Watanabe ToddDirector, See Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$139K
4,377 sh
Nov 2, 2026Nov 4, 2026
traded Nov 2, 2026
+2dSEC FORM 4

Evidence

15
SA
Scott Robert ADirector
ARQTArcutis Biotherapeutics, Inc.
Grant or award
A—
8,663 sh
Oct 23, 2026Oct 28, 2026
traded Oct 23, 2026
+5dSEC FORM 4

Evidence

15
SA
Scott Robert ADirector
ARQTArcutis Biotherapeutics, Inc.
Grant or award
A—
20.5K sh
Oct 23, 2026Oct 28, 2026
traded Oct 23, 2026
+5dSEC FORM 4

Evidence

15
SA
Scott Robert ADirector
ARQTArcutis Biotherapeutics, Inc.
Grant or award
A—
2,819 sh
Oct 23, 2026Oct 28, 2026
traded Oct 23, 2026
+5dSEC FORM 4

Evidence

1
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$92K
3,674 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

10
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$250K
9,989 sh
Sep 8, 2026Sep 10, 2026
traded Sep 8, 2026
+2dSEC FORM 4

Evidence

9
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
27.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

9
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
11.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

44
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$677K
27.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

24
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$233K
27.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

40
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$279K
11.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

20
CT
Curran TerrieDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$84K
11.1K sh
Aug 27, 2026Aug 28, 2026
traded Aug 27, 2026
+1dSEC FORM 4

Evidence

9
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
8,300 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

24
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$220K
8,300 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

9
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$24K
6,700 sh
Aug 12, 2026Aug 13, 2026
traded Aug 12, 2026
+1dSEC FORM 4

Evidence

9
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$30K
8,300 sh
Aug 11, 2026Aug 13, 2026
traded Aug 11, 2026
+2dSEC FORM 4

Evidence

9
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
6,700 sh
Aug 12, 2026Aug 13, 2026
traded Aug 12, 2026
+1dSEC FORM 4

Evidence

24
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$175K
6,700 sh
Aug 12, 2026Aug 13, 2026
traded Aug 12, 2026
+1dSEC FORM 4

Evidence

20
Gilbert Ray Cisneros, Jr.DSelf
ARQTArcutis Biotherapeutics, Inc.
Purchase
BUY$1,001 – $15KMay 29, 2026Jun 8, 2026
traded May 29, 2026
+10dHOUSE PTR

Evidence

11
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,157
435 sh
May 11, 2026May 13, 2026
traded May 11, 2026
+2dSEC FORM 4

Evidence

11
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$21K
884 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

11
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$32K
1,341 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

14
WT
Watanabe ToddDirector, See Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
3,172 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

18
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$172K
7,372 sh
May 4, 2026May 6, 2026
traded May 4, 2026
+2dSEC FORM 4

Evidence

28
Gilbert Ray Cisneros, Jr.DSelf
ARQTArcutis Biotherapeutics, Inc.
Purchase
BUY$1,001 – $15KMar 3, 2026Apr 7, 2026
traded Mar 3, 2026
+35dHOUSE PTR

Evidence

9
LJ
Lin Sue-JeanDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
7,220 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

9
LJ
Lin Sue-JeanDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M—
18.1K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

16
LJ
Lin Sue-JeanDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$54K
7,220 sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

45
LJ
Lin Sue-JeanDirector
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$778K
25.3K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

24
LJ
Lin Sue-JeanDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise
M$156K
18.1K sh
Nov 24, 2025Nov 25, 2025
traded Nov 24, 2025
+1dSEC FORM 4

Evidence

16
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$44K
1,561 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

16
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$28K
989 sh
Nov 19, 2025Nov 21, 2025
traded Nov 19, 2025
+2dSEC FORM 4

Evidence

38
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$911K
39.3K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

24
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$29K
1,232 sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

0
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M—
12.2K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

14
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M$233K
27.1K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

0
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M—
27.1K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

10
KN
Krishnamohan NehaDirector
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M$92K
12.2K sh
Nov 13, 2025Nov 17, 2025
traded Nov 13, 2025
+4dSEC FORM 4

Evidence

26
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$417K
17.3K sh
Nov 6, 2025Nov 10, 2025
traded Nov 6, 2025
+4dSEC FORM 4

Evidence

46
ET
Edwards Larry ToddSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale
SELL$733K
29.1K sh
Nov 6, 2025Nov 10, 2025
traded Nov 6, 2025
+4dSEC FORM 4

Evidence

0
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M—
17.3K sh
Nov 6, 2025Nov 10, 2025
traded Nov 6, 2025
+4dSEC FORM 4

Evidence

2
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Option exercise · 10b5-1 plan
M$63K
17.3K sh
Nov 6, 2025Nov 10, 2025
traded Nov 6, 2025
+4dSEC FORM 4

Evidence

19
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$92K
3,864 sh
Nov 5, 2025Nov 5, 2025
traded Nov 5, 2025
+0dSEC FORM 4

Evidence

26
WT
Watanabe ToddDirector, See Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$284K
11.5K sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

20
WT
Watanabe ToddDirector, See Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1,753
69 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

30
WG
Welgus Howard G.Director
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$253K
10.0K sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

23
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$177K
7,165 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

20
MM
Matsuda MasaruSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1,092
43 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

23
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$64K
2,607 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

20
BP
Burnett PatrickSee Remarks
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$381
15 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

20
VL
Vairavan LathaSVP Chief Financial Officer
ARQTArcutis Biotherapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$2,175
88 sh
Nov 3, 2025Nov 5, 2025
traded Nov 3, 2025
+2dSEC FORM 4

Evidence

← Insider ofevidence
Lin Sue-Jean
Director · Nov 25, 2025
  • ← Insider ofevidence
    Krishnamohan NehaDirector · Nov 17, 2025
  • ← Insider ofevidence
    Edwards Larry ToddSee Remarks · Nov 10, 2025
  • ← Insider ofevidence
    Matsuda MasaruSee Remarks · Nov 5, 2025
  • ← Insider ofevidence
    Welgus Howard G.Director · Nov 5, 2025
  • ← Insider ofevidence
    Burnett PatrickSee Remarks · Nov 5, 2025
  • ← Insider ofevidence
    Watanabe ToddDirector, See Remarks · Nov 5, 2025
  • ← Insider ofevidence
    Vairavan LathaSVP Chief Financial Officer · Nov 5, 2025